Kit formulation of Bevacizumab, an anti-VEGF monoclonal antibody, and consequent labelling with Rhenium-188: initial in vitro and in vivo studies

被引：0
|
作者：
Bouziotis, P. [1 ]
Gourni, E. [1 ]
Xanthopoulos, S. [1 ]
Paravatou, M. [1 ]
Syrigos, K. [2 ]
Loudos, G. [3 ]
Archimandritis, S. C. [1 ]
Varvarigou, A. D. [1 ]
Harris, A. L. [4 ]
机构：
[1] NCSR Demokritos, Inst Radioisotopes & Radiodiagnost Prod, Athens, Greece
[2] Sotiria Gen Hosp, Dept Med 3, Med Oncol Unit, Athens, Greece
[3] Technol Educ Inst Athens, Dept Med Instruments Technol, Athens, Greece
[4] Univ Oxford, Inst Mol Med, Mol Oncol Lab, Oxford, England
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S320 / S321
页数：2
相关论文
共 48 条
  • [21] Phase it study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): Preliminary results
    Gotlib, J
    Jamieson, CHM
    List, A
    Cortes, J
    Albitar, M
    Sridhar, K
    Dugan, K
    Quesada, S
    Diaz, G
    Pate, O
    Novotny, W
    Chen, H
    Greenberg, PL
    BLOOD, 2003, 102 (11) : 425A - 425A
  • [22] Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors - a review of radiolabeling characteristics, quality control and in vitro stability studies
    Iznaga-Escobar, N
    APPLIED RADIATION AND ISOTOPES, 2001, 54 (03) : 399 - 406
  • [23] Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice
    Yasumichi Yagi
    Sachio Fushida
    Shinichi Harada
    Tomoya Tsukada
    Jun Kinoshita
    Katsunobu Oyama
    Hideto Fujita
    Itasu Ninomiya
    Takashi Fujimura
    Masato Kayahara
    Seigo Kinuya
    Masakazu Yashiro
    Kousei Hirakawa
    Tetsuo Ohta
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 745 - 753
  • [24] Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma
    Kasuya, Kazuhiko
    Nagakawa, Yuichi
    Suzuki, Minako
    Suzuki, Yoshiaki
    Kyo, Bunso
    Suzuki, Satoru
    Matsudo, Takaaki
    Itoi, Takao
    Tsuchida, Akihiko
    Aoki, Tatsuya
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (04) : 599 - 602
  • [25] Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice
    Yagi, Yasumichi
    Fushida, Sachio
    Harada, Shinichi
    Tsukada, Tomoya
    Kinoshita, Jun
    Oyama, Katsunobu
    Fujita, Hideto
    Ninomiya, Itasu
    Fujimura, Takashi
    Kayahara, Masato
    Kinuya, Seigo
    Yashiro, Masakazu
    Hirakawa, Kousei
    Ohta, Tetsuo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 745 - 753
  • [26] Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers.
    Wheler, J. J.
    Janku, F.
    Jackson, T.
    Fu, S.
    Sun, M.
    Yang, H.
    Naing, A.
    Moulder, S. L.
    Tsimberidou, A. M.
    Hong, D. S.
    Falchook, G. S.
    Piha-Paul, S. A.
    Garcia-Manero, G.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Wheler, Jennifer J.
    Janku, Filip
    Falchook, Gerald S.
    Jackson, Tiffiny L.
    Fu, Siqing
    Naing, Aung
    Tsimberidou, Apostalia M.
    Moulder, Stacy L.
    Hong, David S.
    Yang, Hui
    Piha-Paul, Sarina A.
    Atkins, Johnique T.
    Garcia-Manero, Guillermo
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 495 - 501
  • [28] Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Jennifer J. Wheler
    Filip Janku
    Gerald S. Falchook
    Tiffiny L. Jackson
    Siqing Fu
    Aung Naing
    Apostalia M. Tsimberidou
    Stacy L. Moulder
    David S. Hong
    Hui Yang
    Sarina A. Piha-Paul
    Johnique T. Atkins
    Guillermo Garcia-Manero
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 495 - 501
  • [29] Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo
    Liu, Lin
    Qin, Shukui
    Zheng, Yinghui
    Han, Li
    Zhang, Minmin
    Luo, Nuo
    Liu, Zhengcao
    Gu, Ning
    Gu, Xiaoyi
    Yin, Xiaojin
    CANCER BIOLOGY & THERAPY, 2017, 18 (03) : 166 - 176
  • [30] Importance of VEGF for breast cancer angiogenesis in vivo implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
    Borgstrom, P
    Gold, DP
    Hillan, KJ
    Ferrara, N
    ANTICANCER RESEARCH, 1999, 19 (5B) : 4203 - 4214
12345